These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36107723)

  • 1. Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives.
    Wei GX; Du Y; Zhou YW; Li LJ; Qiu M
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):851-861. PubMed ID: 36107723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current status of immunotherapy in peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM; Jauch KW
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1019-27. PubMed ID: 27530056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
    Ornella MSC; Badrinath N; Kim KA; Kim JH; Cho E; Hwang TH; Kim JJ
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
    Goéré D; Gras-Chaput N; Aupérin A; Flament C; Mariette C; Glehen O; Zitvogel L; Elias D
    BMC Cancer; 2014 Mar; 14():148. PubMed ID: 24589307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal immunotherapy: historical perspectives and modern therapy.
    Morano WF; Aggarwal A; Love P; Richard SD; Esquivel J; Bowne WB
    Cancer Gene Ther; 2016 Nov; 23(11):373-381. PubMed ID: 27834358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
    Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
    Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale.
    Roviello F; Caruso S; Neri A; Marrelli D
    Eur J Surg Oncol; 2013 Dec; 39(12):1309-16. PubMed ID: 24183797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.
    Tonello M; Ortega-Perez G; Alonso-Casado O; Torres-Mesa P; Guiñez G; Gonzalez-Moreno S
    Clin Transl Oncol; 2018 Oct; 20(10):1268-1273. PubMed ID: 29667123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
    Qian S; Villarejo-Campos P; García-Olmo D
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.
    Kitayama J
    Surg Oncol; 2014 Jun; 23(2):99-106. PubMed ID: 24721661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
    Koppe MJ; Boerman OC; Oyen WJ; Bleichrodt RP
    Ann Surg; 2006 Feb; 243(2):212-22. PubMed ID: 16432354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.
    Katz SC; Point GR; Cunetta M; Thorn M; Guha P; Espat NJ; Boutros C; Hanna N; Junghans RP
    Cancer Gene Ther; 2016 May; 23(5):142-8. PubMed ID: 27080226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies.
    Ströhlein MA; Heiss MM
    J Surg Oncol; 2009 Sep; 100(4):329-30. PubMed ID: 19697440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.
    Klaver CE; Musters GD; Bemelman WA; Punt CJ; Verwaal VJ; Dijkgraaf MG; Aalbers AG; van der Bilt JD; Boerma D; Bremers AJ; Burger JW; Buskens CJ; Evers P; van Ginkel RJ; van Grevenstein WM; Hemmer PH; de Hingh IH; Lammers LA; van Leeuwen BL; Meijerink WJ; Nienhuijs SW; Pon J; Radema SA; van Ramshorst B; Snaebjornsson P; Tuynman JB; Te Velde EA; Wiezer MJ; de Wilt JH; Tanis PJ
    BMC Cancer; 2015 May; 15():428. PubMed ID: 26003804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer.
    Miller AM; Lemke-Miltner CD; Blackwell S; Tomanek-Chalkley A; Gibson-Corely KN; Coleman KL; Weiner GJ; Chan CHF
    Ann Surg Oncol; 2021 Feb; 28(2):1187-1197. PubMed ID: 32409965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.